Case reports: Sorafenib-induced palmoplantar hyperkeratosis

Journal of Drugs in Dermatology

Volumn 7, Issue 6, 2008, Pages 588-589

  Lountzis, Nektarios I ^a   Maroon, Michele S ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; SORAFENIB;

ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; PALMOPLANTAR KERATODERMA; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KERATODERMA, PALMOPLANTAR; KIDNEY NEOPLASMS; MIDDLE AGED; PYRIDINES;

EID: 47249141584     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007 Feb;56:317-326. (Pubitemid 46091817)
2. Morabito A, De Maio E, Di Maio M, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. The Oncologist. 2006; 11:753-764. (Pubitemid 44157563)
3. Escudier B, Eisen T, Stadler WM, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
4. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10 (suppl):S6388-S6392.
5. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109. (Pubitemid 39331023)
6. MacGregor JL, Silvers DN, Grossman ME, et al. Sorafenib-induced erythema multiforme. J Am Acad Dermatol. 2007;56:527-528. (Pubitemid 46273859)
7. Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol. 2007;56:171-172.
8. Lacouture ME, Desai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine- kinase inhibitor. Clin Exp Dermatol. 2006;31:783-785. (Pubitemid 44563396)
9. Chung NM, Gutierrez M, Turner ML. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib. Arch Dermatol. 2006;142:1510-1511. (Pubitemid 44790655)
10. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491-500. (Pubitemid 40903630)